Research Article

Analysis of Expression of Vascular Endothelial Growth Factor A and Hypoxia Inducible Factor-1alpha in Patients Operated on Stage I Non-Small-Cell Lung Cancer

Antonio Francisco Honguero Martínez, 1 Antonio Arnau Obrer, 2 Santiago Figueroa Almánzar, 3 Pablo León Atance, 1 and Ricardo Guijarro Jorge 2

1 Thoracic Surgery, University General Hospital of Albacete, 37 Hermanos Falcó Street, 02006 Albacete, Spain
2 Thoracic Surgery, University General Hospital of Valencia and Surgery Department of the School of Medicine and Odontology, University of Valencia, 15 Blasco Ibíñez Avenue, 46010 Valencia, Spain
3 Thoracic Surgery, University General Hospital of Valencia, Tres Creus Avenue, 46014 Valencia, Spain

Correspondence should be addressed to Antonio Francisco Honguero Martínez; tonyhonguero@yahoo.es

Received 10 October 2013; Revised 15 December 2013; Accepted 26 December 2013; Published 10 February 2014

Academic Editor: Akira Iyoda

Copyright © 2014 Antonio Francisco Honguero Martínez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. Recent studies show that expression of hypoxia inducible factor-1alpha (HIF-1α) favours expression of vascular endothelial growth factor A (VEGF-A), and these biomarkers are linked to cellular proliferation, angiogenesis, and metastasis in different cancers. We analyze expression of HIF-1α and VEGF-A to clinicopathologic features and survival of patients operated on stage I non-small-cell lung cancer.

Methodology. Prospective study of 52 patients operated on with stage I. Expression of VEGF-A and HIF-1α was performed through real-time quantitative polymerase chain reaction (qRT-PCR).

Results. Mean age was 64.7 and 86.5% of patients were male. Stage IA represented 23.1% and stage IB 76.9%. Histology classification was 42.3% adenocarcinoma, 34.6% squamous cell carcinoma, and 23.1% others. Median survival was 81.0 months and 5-year survival 67.2%. There was correlation between HIF-1α and VEGF-A (P = 0.016). Patients with overexpression of HIF-1α had a tendency to better survival with marginal statistical significance (P = 0.062). Patients with overexpression of VEGF-A had worse survival, but not statistically significant (P = 0.133).

Conclusion. The present study revealed that VEGF-A showed correlation with HIF-1α. HIF-1α had a tendency to protective effect with a P value close to statistical significance. VEGF-A showed a contrary effect but without statistical significance.

1. Introduction

Lung cancer is one of the most frequent neoplasms with a high global mortality [1, 2]. Prognosis is mainly determined by stage and TNM system, lastly revised in 2009 [3].

Stage I is the initial one and is the time more common due to the more extensive use of computed tomography scan on population. Surgery is the most efficient treatment on stage I. Nevertheless, although being an early stage and being treated by curative surgical resection, cancer related mortality is still high.

Oncology investigations in the last years are basically headed to study molecular biomarkers expression, cellular pathways, and interactions to better understand tumoral biology and develop effective treatment.

A lot of investigations on tumoral biomarkers in lung cancer early stages have been performed [4–6]. Angiogenesis is fundamental to favour tumoral growth [7, 8]. This process consists of formation of new vessels from preexisting ones to provide nutrients and physiological conditions needed to favour tumoral growth and development. Vascular endothelial growth factor A (VEGF-A) is the main angiogenic factor [9, 10] and is related to hypoxia inducible factor-1alpha (HIF-1α) owed to hypoxemic conditions surrounding tumoral growth [11, 12].
We performed a study about the expression of VEGF-A and HIF-\(\alpha\) and their prognosis on patients treated by surgery in stage I non-small-cell lung cancer.

2. Methodology

2.1. Patients. From May 1, 2004 to December 31, 2007, a total of 66 patients took part in this study. All of them were operated on from non-small-cell lung cancer (NSCLC) and were classified into stage I after anatopathologic study. Last 2009 TNM classification was used [3] and histology was done according to the World Health Organization classification [13]. Patients were excluded in the following cases: histology different to NSCLC, rejection to participate in the study, postoperative death (30 first days after intervention or until patient was discharged), tumor samples invalid to be processed, patients treated with induction therapy, or neoplasms in the 5 previous years other than basal cell carcinoma.

Preoperative work-up consisted of physical examination, blood analysis, electrocardiogram, chest X-ray film, and computed tomography (CT) scan of chest and upper abdomen, fiberbronchoscopy, spirometry, and electrocardiogram. Brain CT and bone scintigraphy were performed in case of clinical suspicion. Neither PET nor PET-CT scan was routinely performed because they were not available in that period. Preoperative mediastinal lymph nodes biopsy was performed when nodes’ shortest diameter was superior to 1.0 cm to rule out N2 disease. After pulmonary resection, mediastinal lymph node dissection was done. In this study only patients without lymph node involvement after surgical resection were included.

Followup was done as follows: chest X-ray films two weeks after discharge to check for early postoperative complications, then, thorax and upper abdominal CT-scan every six months for the first two years, and afterwards one annual control in the next years. When tumour relapse was observed, histological confirmation was always attempted when feasible.

Patients signed informed consent and the study was approved by the local Bioethical Committee and by the Investigation Committee.

2.2. RNA Extraction and Reverse Transcription. After surgical resection, specimens of lung cancer and pulmonary parenchyma were collected in RNAlater (Invitrogen, USA) at \(-80^\circ\)C. Total RNA was isolated from resected lung tissues using a RNA extraction reagent (TRI Reagent, Molecular Research Center, Sigma-Aldrich Inc., St. Louis, USA), following the manufacturer’s instructions. Total RNA was digested with DNase at room temperature for 15 min. Five micrograms of digested RNA were reverse transcribed at 37\(^\circ\)C for 120 min in a total reaction volume of 25 \(\mu\)L, using the High-Capacity cDNA Reverse Transcription kit (Foster City, CA, USA).

The extracted RNA was analyzed by agarose gel electrophoresis. Only cases with preserved 28S, 18S indicating good RNA quality were included in this study. Obtained cDNA was used in quantitative real-time PCR reaction (qRT-PCR).

2.3. Detection of Gene Expression Using qRT-PCR. qRT-PCR was performed using master mix prepared according to the TaqMan Universal PCR Master Mix kit (Roche Molecular Systems Inc., Branchburg, NJ, USA). \(\beta\)-Actin was the housekeeping gene (Applied Biosystems, Assay ID: Hs99999903_m1. Amplicon size: 171 pb). VEGF-A and HIF-\(\alpha\) genes were also from Applied Biosystems:

- VEGF-A: assay ID: Hs00900054_m1, 77 pb amplicon;
- HIF-\(\alpha\): assay ID: Hs00153153_m1, 76 pb amplicon.

qRT-PCR was carried out in a final volume of 50 \(\mu\)L, with 0.05 \(\mu\)g cDNA, 25 \(\mu\)L TaqMan Universal PCR Master Mix (Roche Molecular Systems), and 1 \(\mu\)M of each primer. Amplification was performed for 10 min at 95\(^\circ\)C to activate AmpliTaq Gold Polymerase, then 40 rounds of 15 s at 95\(^\circ\)C, and 1 min at 60\(^\circ\)C for amplification and signal analysis. The device used to detect amplifications was ABI Prism 7000 Sequence Detection System from Applied Biosystems (USA). qRT-PCR data were automatically calculated with the data analysis module. Results were expressed as the ratio of expression in tumoral and lung tissues and normalized to the transcription level of the housekeeping gene. Validation of PCR efficiency was performed with a standard curve.

2.4. Statistical Analysis. Data were expressed as mean values \(\pm\) standard deviation (SD) or median values and range. Association between categorical variables was performed using Chi-square or Fisher’s exact test. For quantitative variables Student’s t- or U-Mann-Whitney tests were used.

End of followup was December 31, 2010. The follow-up period was calculated from the date of surgical resection to death or last follow-up date for living patients. Alive and non-tumoral-cause dead patients were regarded as censored observations.

Overall survival curves were estimated using Kaplan-Meier method and compared by log-rank test. Cox proportional hazard regression model was used for multivariate analysis to evaluate the prognostic value of clinicopathological variables with respect to overall survival. All the applied tests were two-sided. The analysis was performed using a statistical software package (SPSS, Inc., version 12.0, Chicago, IL).

Statistical significance was defined as a value of \(P < 0.05\).

3. Results

A total of 52 patients were included according to inclusion/exclusion criteria previously exposed. Male sex was predominant (86.5%) and adenocarcinoma subtype was the most frequent histology (Table 1). Stage IB was the most frequent (76.9%) and median follow-up time was 50 months (range: 1–92). Median survival time was 81.0 months and overall 5-year estimated survival was 67.2%.

Biomarkers VEGF-A and HIF-\(\alpha\) showed a nonnormal distribution. After checking quartile distribution and cancer-related deaths, cut-off points correspondent to 75 percentile (value = 1.74) and median (value = 1.22) values were chosen to consider the overexpression of VEGF-A and HIF-\(\alpha\),
Table 1: Patients’ clinicopathologic characteristics.

| Characteristic | Value |
|----------------|-------|
| Age (mean ± s.d.) | 64.7 years ± 10 |
| Sex M:F (%) | 45 (86.5%):7 (13.5%) |
| Histology | |
| Adenocarcinoma | 22 (42.3%) |
| Epidermoid | 18 (34.6%) |
| Others | 12 (23.1%) |
| T1a | 5 (9.6%) |
| T1b | 7 (13.5%) |
| T2a | 40 (76.9%) |
| Stage | |
| IA | 12 (23.1%) |
| IB | 40 (76.9%) |
| Alive patients | 28 (53.8%) |
| Tumoral related death | 16 (30.8%) |
| Nontumoral related death | 8 (15.4%) |
| Tumoral size (mean ± s.d.) | 3.03 cm ± 1.06 |
| Tumoral relapse | |
| Yes | 20 (38.5%) |
| No | 32 (61.5%) |
| Smoking | |
| Never | 4 (7.7%) |
| Former smoker | 18 (34.6%) |
| Active smoker | 30 (57.7%) |
| Follow-up time (Median [range]) | 50 months (1–92) |
| Resection | |
| Sublobar | 8 (15.4%) |
| Lobectomy | 34 (65.4%) |
| Bilobectomy | 3 (5.8%) |
| Pneumonectomy | 7 (13.5%) |

s.d.: standard deviation; M: male. F: female.

Table 2: Correlation of VEGF-A and HIF-1α with quantitative and qualitative variables.

| Variable | VEGF-A (P) | HIF-1α (P) |
|----------|-----------|------------|
| Quantitative variables | |
| Tumor size | 0.134 | 0.175 |
| Smoking (pack-year) | 0.051 | 0.061 |
| Preoperative haemoglobin | 0.323 | 0.491 |
| Age | 0.298 | 0.347 |
| VEGF-A | — | 0.016* |
| HIF-1α | 0.016* | — |
| Qualitative variables | |
| Sex | 0.664 | 1.000 |
| T1/T2 | 1.000 | 0.001* |
| Histology | 0.302 | 0.496 |
| Recidive (yes/no) | 0.211 | 0.910 |
| State (alive/dead) | 0.351 | 0.171 |

*Statistical significance (P < 0.05).

Table 3: Univariate analysis of prognostic factors on survival.

| Variables | P | O.R. (C.I. 95%) |
|-----------|---|----------------|
| VEGF-A | 0.145 | 2.162 (0.766–6.107) |
| HIF-1α | 0.074 | 0.379 (0.131–1.100) |
| T1/T2 | 0.955 | 0.968 (0.312–3.003) |
| Histology | 0.496 | |
| Type of resection | 0.180 | |

O.R.: odds ratio; C.I.: confidence interval.

respectively. Correlation between VEGF-A and HIF-1α as quantitative variables was statistically significant (P = 0.016) with Pearson’s correlation coefficient of 0.33 (Figure 1). There was also statistical significance between HIF-1α and T descriptor (P = 0.001). This way, overexpression of HIF-1α in T2 tumors was higher than in T1 tumors (Table 2). Survival analysis revealed a tendency toward better prognosis in patients with HIF-1α overexpression (P = 0.062, Figure 2) and a tendency to a worse prognosis in patients with VEGF-A overexpression (Figure 3). At univariate analysis of Cox proportional hazard model on survival none of the variables reached statistical significance (Table 3). Nevertheless, HIF-1α showed the P value closest to statistical significance (P = 0.074) and an odds ratio value <1, reflecting its protective effect.

4. Discussion

In lung cancer, stage IA is one of the less frequent. It usually happens at radiology exploration (chest X-ray film, CT scan, etc.) performed for other reasons and a pulmonary solitary nodule is discovered. On the contrary, stage IB is the most frequent among patients operated on lung cancer. It encompasses tumors superior to 3 cm to up to 5 cm in diameter [3]. An early diagnosis is important in lung cancer due to its relevance on prognosis. However, lung cancer on early stage has a 5-year survival range between 73 and 57% [14, 15]. Currently, TNM system is the one used to classify disease extension and prognosis. It uses descriptors based on invasion or tumoral extension into anatomic or anathomopathologic elements, as a result of expression and evolution of molecular and cellular changes in cancer cells. In the last years, there is a proliferation of works involving biomolecular studies of cancer in general, and also lung cancer in particular, attending complicated pathways in cell proliferation, tumoral invasion, and metastasis [6, 16–20]. A solid tumor needs vascular vessels to provide them with nutrients to grow and a way to eliminate their metabolism-derived products.

This neovascularization arising from preexisting vessels is called neoangiogenesis [21]. When a tumor reaches more than 2-3 mm³ in size, a situation of cellular hypoxia occurs favoring expression of HIF-1α. This protein is translocated into the cellular nucleus and activates dozens of genes, such as VEGF-A [11, 22]. We observed a direct relation between VEGF-A and HIF-1α with statistical significance (P = 0.016), similar to that described by other authors [23, 24]. However, correlation coefficient (r) was low (0.33), as opposed to 0.67 observed by Kim et al. [25]. A possible explanation could
Figure 1: Scatter plot diagram between VEGF-A and HIF-1α. Determination coefficient ($r^2$) = 0.04. Correlation coefficient ($r$) = 0.33.

Figure 2: Survival curve according to expression of HIF-1α (log-rank test). Overexpression of HIF-1α when its level was superior to its median value (1.22).

Figure 3: Survival curve according to the expression of VEGF-A (log-rank test). Overexpression of VEGF-A when its level was superior to percentile 75 (1.74).
In this way, studies in phase III have not yet been underscored with biomolecular profile expressed by his or her tumor. It becomes possible to offer every single patient a treatment in accordance to their tumoral expression. In the future, it may be possible to offer every single patient a treatment in accordance with biomolecular profile expressed by his or her tumor [34]. In this way, studies in phase III have not yet been undergone administering bevacizumab (monoclonal antibody) in patients with overexpression of VEGF-A [35]. For this reason, it is necessary to carry out more studies on this subject to get a deeper knowledge and to establish a path steadier on prognosis and treatment of this disease.

In conclusion, correlation between HIF-1α and VEGF-A was observed in patients operated on stage I NSCLC. HIF-1α showed a tendency to protective effect on overall survival. VEGF-A overexpression showed an opposed effect (worse prognosis), although differences did not reach statistical significance.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**References**

[1] D. R. Youlden, S. M. Cramb, and P. D. Baade, "The international epidemiology of lung cancer: geographical distribution and secular trends," *Journal of Thoracic Oncology*, vol. 3, no. 8, pp. 819–831, 2008.

[2] E. F. Fernández, J. M. Borrás, F. Levi, A. Schiaffino, M. Garcia, and C. Vecchia, "Mortalidad por cáncer en España," *Medicina Clínica*, vol. 114, pp. 449–451, 2000.

[3] F. C. Dettbeck, D. J. Boffa, and L. T. Tanoue, "The new lung cancer staging system," *Chest*, vol. 136, no. 1, pp. 260–271, 2009.

[4] A. L. Encuentra, F. L. Ríos, E. Conde et al., "Composite anatomical-clinical-molecular prognostic model in non-small cell lung cancer," *The European Respiratory Journal*, vol. 37, pp. 136–142, 2011.

[5] J. K. Field, T. Lioglou, A. Niaz et al., "EUELC project: a multicentre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration," *The European Respiratory Journal*, vol. 34, no. 6, pp. 1477–1486, 2009.

[6] K. Junker, "Prognostic factors in stage I/II non-small cell lung cancer," *Lung Cancer*, vol. 33, supplement 1, pp. S17–S24, 2001.

[7] J. Folkman, "Tumor angiogenesis: therapeutic implications," *The New England Journal of Medicine*, vol. 285, no. 21, pp. 1182–1186, 1971.

[8] G. H. Algire, H. W. Chalkey, E. Y. Legallais, and H. D. Park, "Vascular reactions of normal and malignant tissues in vivo. Vascular reactions in mice to wounds and to normal and neoplastic transplants," *Journal of the National Cancer Institute*, vol. 6, pp. 73–85, 1945.

[9] R. M. Bremnes, C. Camps, and R. Sirera, "Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood," *Lung Cancer*, vol. 51, no. 2, pp. 143–158, 2006.

[10] K. J. O’Byrne, M. I. Koukourakis, A. Giatromanolaki et al., "Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer," *British Journal of Cancer*, vol. 82, no. 8, pp. 1427–1432, 2000.

[11] G. L. Semenza, "Targeting HIF-1 for cancer therapy," *Nature Reviews Cancer*, vol. 3, no. 10, pp. 721–732, 2003.

[12] A. P. Levy, N. S. Levy, and M. A. Goldberg, "Post-transcriptional regulation of vascular endothelial growth factor by hypoxia," *The Journal of Biological Chemistry*, vol. 271, no. 5, pp. 2746–2753, 1996.

[13] W. D. Travis, E. Brambilla, H. K. Müller-Hermelink, and C. C. Harris, Eds., *Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart*, World Health Organization Classification of Tumours, IARC Press, Lyon, France, 2004.

[14] L. Crinò, W. Weder, J. van Meerbeeck, E. Felip, and ESMO Guidelines Working Group, "Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up," *Annals of Oncology*, vol. 21, supplement 5, pp. S103–S115, 2010.

[15] W. R. Smythe, "Treatment of stage I non-small cell lung carcinoma," *Chest*, vol. 123, no. 1, 2003.

[16] M. J. Kim, H.-G. Kang, S. Y. Lee et al., "AKT1 polymorphisms and survival of early stage non-small cell lung cancer," *Journal of Surgical Oncology*, vol. 105, no. 2, pp. 167–174, 2012.

[17] P. A. Lario, B. C. García, and E. M. Elizondo, "Expresión de proteínas relacionadas con resistencia en el cáncer de pulmón," *Cirugía Española*, vol. 79, pp. 46–56, 2006.

[18] M. Liao, H. Wang, Z. Lin, J. Feng, and D. Zhu, "Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer," *Lung Cancer*, vol. 33, no. 2–3, pp. 125–132, 2001.

[19] K.-I. Minami, Y. Saito, H. Imamura, and A. Okamura, "Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung," *Lung Cancer*, vol. 38, no. 1, pp. 51–57, 2002.

[20] M. L. Maestro de las Casas, R. R. Sánchez, M. T. Sanz Casla, A. T. García, and J. L. Balibrea, "Cáncer de pulmón: hacia un nuevo concepto de marcador tumoral," *Cirugía Española*, vol. 63, pp. 53–60, 1998.

[21] J. Folkman, "Tumor angiogenesis: therapeutic implications," *The New England Journal of Medicine*, vol. 285, no. 21, pp. 1182–1186, 1971.

[22] P. Jaakkola, D. R. Mole, Y.-M. Tian et al., "Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2−-regulated prolyl hydroxylation," *Science*, vol. 292, no. 5516, pp. 468–472, 2001.

[23] S. Enatsu, A. Iwasaki, T. Shirakusa et al., "Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung," *European Journal of Cardio-Thoracic Surgery*, vol. 29, no. 6, pp. 891–895, 2006.

[24] A. Giatromanolaki, M. I. Koukourakis, E. Sivridis et al., "Relation of hypoxia-inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival," *British Journal of Cancer*, vol. 85, no. 6, pp. 881–890, 2001.
[25] S. J. Kim, Z. N. Rabbani, M. W. Dewhirst et al., “Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer,” Lung Cancer, vol. 49, no. 3, pp. 325–335, 2005.

[26] M. Höckel and P. Vaupel, “Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects,” Journal of the National Cancer Institute, vol. 93, no. 4, pp. 266–276, 2001.

[27] P. Zhan, J. Wang, X.-J. Lv et al., “Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis,” Journal of Thoracic Oncology, vol. 4, no. 9, pp. 1094–1103, 2009.

[28] P. Delmotte, B. Martin, M. Paesmans et al., “The role of vascular endothelial growth factor in the survival of patients with lung cancer: a systematic literature review and meta-analysis,” Revue des Maladies Respiratoires, vol. 19, no. 5, pp. 577–584, 2002.

[29] J.-J. Hung, M.-H. Yang, H.-S. Hsu, W.-H. Hsu, J.-S. Liu, and K.-J. Wu, “Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer,” Thorax, vol. 64, no. 12, pp. 1082–1089, 2009.

[30] A. Lidgren, Y. Hedberg, K. Grankvist, T. Rasmuson, J. Vasko, and B. Ljungberg, “The expression of hypoxia-inducible factor α is a favorable independent prognostic factor in renal cell carcinoma,” Clinical Cancer Research, vol. 11, no. 3, pp. 1129–1135, 2005.

[31] M. Volm and R. Koomägi, “Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer,” Anticancer Research, vol. 20, no. 3, pp. 1527–1533, 2000.

[32] G. Powis and L. Kirkpatrick, “Hypoxia inducible factor-1α as a cancer drug target,” Molecular Cancer Therapeutics, vol. 3, no. 5, pp. 647–654, 2004.

[33] W.-H. Kuo, C.-M. Shih, C.-W. Lin et al., “Association of hypoxia inducible factor-1α polymorphisms with susceptibility to non-small-cell lung cancer,” Translational Research, vol. 159, no. 1, pp. 42–50, 2012.

[34] V. R. Adams and R. D. Harvey, “Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology,” American Journal of Health-System Pharmacy, vol. 67, supplement 1, pp. 53–59, 2010.

[35] M. Reck, J. Von Pawel, P. Zatloukal et al., “Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAI,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1227–1234, 2009.